CheckMate -649, a pivotal phase III trial evaluating Opdivo plus chemotherapy compared to chemotherapy alone as a first-line treatment for metastatic gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma, met both primary endpoints of overall survival at a pre-specified interim analysis and progression-free survival at final analysis in patients whose tumors express PD-L1 with a combined positive score (CPS) ≥ 5.
Elizabeth Comen originally set out to write a book about the wellness industry, but ended up writing a different book altogether.
